undefined undefined
NaN.000
NaN.00%
Avenue Therapeutics (NASDAQ:ATXI) has filed a prospectus related to the resale of 1.42M shares of common stock. The shares are set to be issued in three tranches, comprised of 689,680 series C warrant...
今天 03:14
First quarter Diluted Earnings Per Share were $0.98 in 2024 vs. $1.00 in 2023 Guidance Range for 2024 Affirmed at $4.52 to $4.72 per Diluted Share ST. LOUIS, May 2, 2024 /PRNewswire/ -- Amer...
05-03 05:00
Gainers: Collective Audience (CAUD) +93%. Deciphera Pharmaceuticals (DCPH) +72%. HWH International (HWH) +40%. Mullen Automotive (MULN) +32%. SEP Acquisition Corp. (SEPA) +30%. Bit Origin Ltd (BTOG) +...
04-30 00:31
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
04-30 00:10
Avenue Therapeutics shares are trading lower by 20.7% during Monday's session. The company announced the exercise of warrants for $4.4 million in gross proceeds.
04-29 22:59
Gainers: Deciphera Pharmaceuticals (DCPH) +72%. Koninklijke Philips N.V. ADR (PHG) +35%. ImmunityBio (IBRX) +38%. Soleno Therapeutics (SLNO) +31%. ZyVersa Therapeutics (ZVSA) +23%. Losers: Clever Leav...
04-29 22:02
Losers: Clever Leaves Holdings (CLVR) -61% announces Voluntary Delisting and SEC Deregistration. Addex Therapeutics Ltd (ADXN) -52% provides update on ADX71149 phase 2 Epilepsy study. Cyclacel Pharmac...
04-29 20:17
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around...
04-24 22:30
Specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, Avenue Therapeutics (NASDAQ:ATXI) will effect a 1-for-75 revers...
04-24 19:58
Project awarded based on sound design plans and lower cost ST. LOUIS, April 3, 2024 /PRNewswire/ -- A subsidiary of St. Louis-based Ameren Corporation has been selected by the regional trans...
04-04 03:08